Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection

The multidrug-resistant (MDR) human immunodeficiency virus 1 (HIV-1) infection is an unmet medical need. HIV-1 capsid plays an important role at different stages of the HIV-1 replication cycle and is an attractive drug target for developing therapies against MDR HIV-1 infection. Lenacapavir (LEN) is...

Descrición completa

Detalles Bibliográficos

Principais autores:	Tafadzwa Dzinamarira, Mazen Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A. Rabaan, Amal H. Alfaraj, Bashayer M. AlShehail, Nouf Alotaibi, Shams M. AlShehail, Mohd Imran
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2023-05-01
Series:	Medicina
Assuntos:	Lenacapavir Sunlenca GS-6207 HIV-1 capsid patent prospects
Acceso en liña:	https://www.mdpi.com/1648-9144/59/6/1041
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!